BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31876778)

  • 1. Pediatric B-lineage Acute Lymphoblastic Leukemia With CD56 Expression: A Report of 2 Cases.
    Aoki M; Kobayashi K; Taji Y; Shimizu Y; Ohta A; Watanabe A; Fukushima T; Tanaka R; Ebihara Y
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):249-250. PubMed ID: 31876778
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients.
    Aref S; Azmy E; El-Bakry K; Ibrahim L; Mabed M
    Hematology; 2018 Jun; 23(5):263-270. PubMed ID: 29161980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low CtBP2 expression is associated with a stem cell-like signature and adverse clinical outcome in childhood B-cell lymphoblastic leukemia.
    Chun S; Kim HY; Kim HJ; Koo HH; Yoo KH; Kim SH; Zhou M; Lee ST; Wiemels JL
    Leukemia; 2021 Sep; 35(9):2684-2687. PubMed ID: 33580202
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
    Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
    Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD7 aberrant expression led to a lineage switch at relapsed childhood acute pre-B lymphoblastic leukemia.
    Fallah Azad V; Hedayati Asl AA; Tashvighi M; Niktoreh Mofrad N; Haghighi M; Mehrvar A
    Med Mol Morphol; 2016 Mar; 49(1):53-6. PubMed ID: 26242204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy.
    Zhang YH; Lu AD; Yang L; Li LD; Chen WM; Long LY; Zhang LP; Qin YZ
    Leuk Res; 2017 Jan; 52():43-49. PubMed ID: 27875783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interference of bone marrow CD56
    Theodorakos I; Paterakis G; Papadakis V; Vicha A; Topakas G; Jencova P; Karchilaki E; Taparkou A; Tsagarakis NJ; Polychronopoulou S
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27799. PubMed ID: 31066205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targets in childhood B-acute lymphoblastic leukemia: what about HER2/neu?
    Camuset M; Huault A; Grain A; Clémenceau B; Rialland F; Thomas C; Chevallier P; Béné MC; Eveillard M
    Hematol Oncol; 2021 Apr; 39(2):270-272. PubMed ID: 32894593
    [No Abstract]   [Full Text] [Related]  

  • 9. [Use of monoclonal antibodies in acute lymphoblastic leukemia in children. II. Clinical picture and prognosis in specific immunological subgroups].
    Kołecki P; Radwańska U
    Pediatr Pol; 1988 Nov; 63(11):698-702. PubMed ID: 3253656
    [No Abstract]   [Full Text] [Related]  

  • 10. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
    Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
    J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
    Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
    Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of myeloid-associated antigen expression on blast cells in children with acute lymphoblastic leukemia. The Austrian Pediatric Oncology Group.
    Fink FM; Köller U; Mayer H; Haas OA; Grümayer-Panzer ER; Urban C; Dengg K; Mutz I; Tüchler H; Gatterer-Menz I
    Med Pediatr Oncol; 1993; 21(5):340-6. PubMed ID: 8492748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive monocytes (CD14
    Lima DS; Lemes RPG; Matos DM
    Med Oncol; 2018 Feb; 35(3):36. PubMed ID: 29429058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD56+ NK lymphomas: clinicopathological features and prognosis.
    Kwong YL; Chan AC; Liang R; Chiang AK; Chim CS; Chan TK; Todd D; Ho FC
    Br J Haematol; 1997 Jun; 97(4):821-9. PubMed ID: 9217183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
    Ravandi F; Cortes J; Estrov Z; Thomas D; Giles FJ; Huh YO; Pierce S; O'Brien S; Faderl S; Kantarjian HM
    Leuk Res; 2002 Jul; 26(7):643-9. PubMed ID: 12008081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.
    Chevallier P; Chantepie S; Huguet F; Raffoux E; Thomas X; Leguay T; Marchand T; Isnard F; Charbonnier A; Maury S; Gallego-Hernanz MP; Robillard N; Guillaume T; Peterlin P; Garnier A; Rialland F; Le Houerou C; Goldenberg DM; Wegener WA; Béné MC; Dombret H
    Haematologica; 2017 May; 102(5):e184-e186. PubMed ID: 28154086
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute lymphoblastic leukaemia with an e1a3 BCR-ABL1 fusion.
    Langabeer SE; Haslam K; Kelly J; Leahy M; Vandenberghe E
    Acta Haematol; 2011; 126(4):214-5. PubMed ID: 21934295
    [No Abstract]   [Full Text] [Related]  

  • 18. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.
    Chevallier P; Huguet F; Raffoux E; Etienne A; Leguay T; Isnard F; Robillard N; Guillaume T; Delaunay J; Charbonnier A; Pigneux A; Peterlin P; Bené MC; Wegener WA; Goldenberg DM; Dombret H
    Haematologica; 2015 Apr; 100(4):e128-31. PubMed ID: 25552705
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic impact of CD200 and CD56 expression in pediatric B-cell acute lymphoblastic leukemia patients.
    Aref S; Azmy E; El-Bakry K; Ibrahim L; Abdel Aziz S
    Pediatr Hematol Oncol; 2017 Aug; 34(5):275-285. PubMed ID: 29144828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD20 has no prognostic significance in children with precursor B-cell acute lymphoblastic leukemia.
    Naithani R; Asim M; Abdelhaleem M; Punnett A
    Haematologica; 2012 Sep; 97(9):e31-2. PubMed ID: 22952332
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.